November 3 2015 Issue

Neurology® Podcast

1) Neurology® Neuroimmunology & Neuroinflammation: Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins and 2) Topic of the month: Neuromyelitis optica. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kelly Gwathmey interviews Dr. Isabel Illa about her Neurology: Neuroimmunology & Neuroinflammation paper on rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Dr. Ted Burns is interviewing Dr. Murray Grossman for our “What's Trending” feature of the week about his paper on the classification of primary progressive aphasia and its variants. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Jeff Bennett about the topic of latest developments in neuromyelitis optica using his antibody library. The participants had nothing to disclose except Drs. Illa, Burns, Grossman, Clardy and Bennett.Dr. Illa received a travel grant from Genzyme; serves as an editorial board member of Neurologia; holds a patent for Dysferlin detection in monocytes; has consulted for Grifols; received research support from Fondo de Investigaciones Sanitarias and ISCIII, Ministry of Health (Spain), Fundacion Gemio.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Grossman serves on the scientific advisory board for Forum; serves as an editorial board member of Neurology®, Journal of Neurolinguistics, Journal of Alzheimer's Disease; serves on the editorial advisory board for Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration; receives research support from Wyncote Foundation, ALS Association and the NIH; received travel funding for a site visit from Max-Planck Society.Dr. Clardy receives research support from the Western Institute for Biomedical Research.Dr. Bennett serves on the scientific advisory board for Apsara Therapeutics; serves as an editorial board member of Journal of Neuro-ophthalmology, Multiple Sclerosis Journal and Neurology® Neuroimmunology and Neuroimflammation; has patents for compositions and methods for the treatment of neuromyelitis optica and novel blocking monoclonal therapy for neuromyelitis optica; is a consultant for EMD-Serono, Questcor Pharmaceuticals, Alnaylam Pharmaceuticals, Medimmune, Abbvie, Novartis, Chugai Pharmaceuticals Co., Ltd., Genzyme Corporation, Genentech, Inc.; receives license fee payments from Aquaporumab; has rights for future royalty payments from Aquaporumab; holds stock options in Apsara Therapeutics; receives research support from Questcor Pharmaceuticals, Novartis, NIH and Guthy-Jackson Foundation.NO CME WILL BE OFFERED THIS WEEK.